RNAM supply chain intelligence for Avidity Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Avidity Biosciences, Inc. (RNAM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense a… |
| PEPG | PepGen Inc. | 72% | Reciprocal relationship from PEPG graph: ed unintended harmful impacts. The use of certain AI technologies can also give rise to intellectual property risks, including by disclosing or otherwise comp… |
| RNA | Atrium Therapeutics, Inc. | 72% | Reciprocal relationship from RNA graph: vate placement at an offering price of $ 16.50 per share and $ 16.499 per pre-funded warrant, which represents the offering price per share of common stock les… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from TRDA g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from DYN grap… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub… |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| EWTX | Edgewise Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| BMRN | BioMarin Pharmaceutical Inc. | 100.00 | 2 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| IONS | Ionis Pharmaceuticals, Inc. | 100.00 | 2 | |
| PEPG | PepGen Inc. | 100.00 | 1 | ['supplier'] |
| WVE | Wave Life Sciences Ltd. | 100.00 | 2 | |
| VRTX | Vertex Pharmaceuticals Incorporated | 100.00 | 2 | |
| IBIO | iBio, Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| TRDA | Entrada Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MYGN | Myriad Genetics, Inc. | 100.00 | 2 |